Physician profile
Albert E Leis
NPI 1831191592
$1,092.47
in general payments reported to CMS, 2019-2025
10 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.66 · 2021: $56.08 · 2022: $148 · 2023: $426 · 2024: $252 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $821.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $441.88 | 2021-2024 | |
| Novo Nordisk INC | $323.50 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $91.10 | 2019-2024 | |
| Glaxosmithkline, LLC. | $65.17 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $46.01 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $41.03 | 2019-2024 | Otezla, Repatha |
| Smith+Nephew, INC. | $31.06 | 2025 | Collagenase Santyl, Iodoflex Dressing 5x5g USA, Iodosorb Ointment 40g USA |
| Lilly USA, LLC | $26.94 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $14.17 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Leis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.